Search

Your search keyword '"Schiappa R"' showing total 272 results
Start Over Author "Schiappa R"
272 results on '"Schiappa R"'

1. Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)

Author

Courtinard, C., Barbet, V., Schiappa, R., Pilleul, F., Michiels, S., Dabakuyo, S., Gourgou, S., Jaffre, A., Asselain, B., Bosquet, L., Dunton, K., Rosenlund, M., Liang, Z., Cathcart, J., and Delaloge, S.

Published
2024
Full Text
View/download PDF

10. Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

Author

Hofman, P., Ilié, M., Chamorey, E., Brest, P., Schiappa, R., Nakache, V., Antoine, M., Barberis, M., Begueret, H., Bibeau, F., Bonnetaud, C., Boström, P., Brousset, P., Bubendorf, L., Carvalho, L., Cathomas, G., Cazes, A., Chalabreysse, L., Chenard, M.-P., Copin, M.-C., Côté, J.-F., Damotte, D., de Leval, L., Delongova, P., Thomas de Montpreville, V., de Muret, A., Dema, A., Dietmaier, W., Evert, M., Fabre, A., Forest, F., Foulet, A., Garcia, S., Garcia-Martos, M., Gibault, L., Gorkiewicz, G., Jonigk, D., Gosney, J., Hofman, A., Kern, I., Kerr, K., Kossai, M., Kriegsmann, M., Lassalle, S., Long-Mira, E., Lupo, A., Mamilos, A., Matěj, R., Meilleroux, J., Ortiz-Villalón, C., Panico, L., Panizo, A., Papotti, M., Pauwels, P., Pelosi, G., Penault-Llorca, F., Pop, O., Poté, N., Cajal, S.R.Y., Sabourin, J.-C., Salmon, I., Sajin, M., Savic-Prince, S., Schildhaus, H.-U., Schirmacher, P., Serre, I., Shaw, E., Sizaret, D., Stenzinger, A., Stojsic, J., Thunnissen, E., Timens, W., Troncone, G., Werlein, C., Wolff, H., Berthet, J.-P., Benzaquen, J., Marquette, C.-H., Hofman, V., and Calabrese, F.

Published
2021
Full Text
View/download PDF

19. CO10.2 - Comparaison de différentes méthodes de machine learning supervisé pour l'aide au diagnostic médical des nodules thyroïdiens

Author

Gal, J., primary, Benidir, S., additional, D'andréa, G., additional, Gilet, C., additional, Chateau, Y., additional, Large, L. Le, additional, Ouaret, L., additional, Dutreve, C., additional, Schiappa, R., additional, Bozec, A., additional, Pace-Loscos, T., additional, Fillatre, L., additional, Culié, D., additional, and Chamorey, E., additional

Published
2023
Full Text
View/download PDF

26. Second conservative treatment for local recurrence breast cancer: a GEC-ESTRO oncological outcome and prognostic factor analysis

Author

Hannoun-Levi, J M, Gal, J, Polgar, C, Strnad, V, Loessl, K, Polat, B, Kauer-Domer, D, Schiappa, R, and Gutierrez, C

Subjects
610 Medicine & health
Abstract

OBJECTIVE For ipsilateral second breast tumor event (2ndIBTE), second conservative treatment (2ndCT) combining lumpectomy plus accelerated partial breast re-irradiation (APBrI) represents a curative option. The aim of this study was to analyze oncological prognostic factors for 2ndIBTE patients treated with 2ndCT. MATERIAL AND METHODS An analysis of clinical practices was conducted across 7 academic hospitals/cancer centers in 6 European countries based on the XXXX database. Patients presenting a 2ndIBTE occurring after conservative surgery (lumpectomy+axillary evaluation) and irradiation performed for the primary tumor, underwent a 2ndCT with brachytherapy based APBrI. The main outcome was 5-year cumulative incidence (CI) rate of second local relapse (2ndLR). All analyzed patients were classified according to risk groups for GEC-ESTRO APBI (APBI) and molecular classification (Mol.) and time interval between first and second breast surgery (TIS1S2). Finally, we combined GEC-ESTRO APBI, molecular and TIS1S2 risk groups, leading to the definition of a new score (named "TAM") specifically designed for 2ndIBTE oncological outcome analysis. RESULTS From 07/1994 and 01/2021, a total of 508 patients received a 2ndCT. At the time of 2ndIBTE, median age was 64.6 years [56.2-72.6]. With a median follow-up of 60.9 months [56.2-72.6], 5-year 2ndLR CI rate was 4% [95%CI 2-6]. Five-year distant metastasis disease CI rate was 7% [95%CI 4-10]. Five-year disease-free and overall survival rates were 89% [95%CI 86-93] and 91% [95%CI 88-94] respectively. In multivariate analysis, TAM score was an independent prognostic factor for all the oncological items (p

Published
2023
Full Text
View/download PDF

35. Efficacité et toxicité de la curiethérapie prostatique en complément après radiothérapie externe pour les cancers de prostate de risque intermédiaire ou élevé : étude rétrospective multicentrique du groupe curiethérapie de la SFRO

Author

Ka, K., primary, Schiappa, R., additional, Mallet, F., additional, Martin, E., additional, Chand, M.-È., additional, Demogeot, N., additional, Bossi, A., additional, Peiffert, D., additional, Quivrin, M., additional, Kissel, M., additional, Hannoun-Lévi, J.-M., additional, and Blanchard, P., additional

Published
2021
Full Text
View/download PDF

44. A refined molecular taxonomy of breast cancer

Author

Guedj, M, Marisa, L, de Reynies, A, Orsetti, B, Schiappa, R, Bibeau, F, MacGrogan, G, Lerebours, F, Finetti, P, Longy, M, Bertheau, P, Bertrand, F, Bonnet, F, Martin, A L, Feugeas, J P, Bièche, I, Lehmann-Che, J, Lidereau, R, Birnbaum, D, Bertucci, F, de Thé, H, and Theillet, C

Published
2012
Full Text
View/download PDF

46. 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns

Author

Humbert, O., primary, Cadour, N., additional, Paquet, M., additional, Schiappa, R., additional, Poudenx, M., additional, Chardin, D., additional, Borchiellini, D., additional, Benisvy, D., additional, Ouvrier, M. J., additional, Zwarthoed, C., additional, Schiazza, A., additional, Ilie, M., additional, Ghalloussi, H., additional, Koulibaly, P. M., additional, Darcourt, J., additional, and Otto, J., additional

Published
2019
Full Text
View/download PDF

47. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study

Author

van der Valk, MJM, Hilling, DE, Bastiaannet, E, Meershoek-Klein Kranenbarg, E, Beets, GL, Figueiredo, NL, Habr-Gama, A, Perez, RO, Renehan, AG, van de Velde, CJH, IWWD Consortium, Ahlberg, M, Appelt, A, Asoglu, O, Bär, M-T, Barroca, R, Beets-Tan, RGH, Belgers, EHJ, Bosker, RJI, Breukink, SO, Bujko, K, Carvalho, C, Cunningham, C, Creavin, B, D'Hoore, A, Gérard, J-P, Gollins, S, Hoff, C, Holman, FA, Hupkens, BJP, Iseas, S, Jakobsen, A, Keshvari, A, Koopal, SA, Kusters, M, Langheinrich, M, Leijtens, JWA, Maas, M, Malcomson, L, Mamedli, ZZ, Martling, A, Matzel, KE, Melenhorst, J, Morici, ML, Murad-Regadas, SM, O'Dwyer, ST, Peeters, KCMJ, Rosa, I, Rossi, G, Rutten, HJT, Sanchez Loria, F, van der Sande, ME, São Julião, GP, Saunders, M, Sun Myint, A, van der Sluis, H, Schiappa, R, Scott, N, Stoot, JHMB, Talsma, AK, Terrasson, I, Tokmak, H, Vaccaro, CA, Vahrmeijer, AL, Wasowicz, DK, Westreenen, HL, Winter, DC, Wolthuis, AM, and Zimmerman, DDE

Abstract

Background: The strategy of watch and wait (W&W) in patients with rectal cancer who achieve a complete clinical response (cCR) after neoadjuvant therapy is new and offers an opportunity for patients to avoid major resection surgery. However, evidence is based on small-to-moderate sized series from specialist centres. The International Watch & Wait Database (IWWD) aims to describe the outcome of the W&W strategy in a large-scale registry of pooled individual patient data. We report the results of a descriptive analysis after inclusion of more than 1000 patients in the registry. Methods: Participating centres entered data in the registry through an online, highly secured, and encrypted research data server. Data included baseline characteristics, neoadjuvant therapy, imaging protocols, incidence of local regrowth and distant metastasis, and survival status. All patients with rectal cancer in whom the standard of care (total mesorectal excision surgery) was omitted after neoadjuvant therapy were eligible to be included in the IWWD. For the present analysis, we only selected patients with no signs of residual tumour at reassessment (a cCR). We analysed the proportion of patients with local regrowth, proportion of patients with distant metastases, 5-year overall survival, and 5-year disease-specific survival. Findings: Between April 14, 2015, and June 30, 2017, we identified 1009 patients who received neoadjuvant treatment and were managed by W&W in the database from 47 participating institutes (15 countries). We included 880 (87%) patients with a cCR. Median follow-up time was 3·3 years (95% CI 3·1–3·6). The 2-year cumulative incidence of local regrowth was 25·2% (95% CI 22·2–28·5%), 88% of all local regrowth was diagnosed in the first 2 years, and 97% of local regrowth was located in the bowel wall. Distant metastasis were diagnosed in 71 (8%) of 880 patients. 5-year overall survival was 85% (95% CI 80·9–87·7%), and 5-year disease-specific survival was 94% (91–96%). Interpretation: This dataset has the largest series of patients with rectal cancer treated with a W&W approach, consisting of approximately 50% data from previous cohort series and 50% unpublished data. Local regrowth occurs mostly in the first 2 years and in the bowel wall, emphasising the importance of endoscopic surveillance to ensure the option of deferred curative surgery. Local unsalvageable disease after W&W was rare. Funding: European Registration of Cancer Care financed by European Society of Surgical Oncology, Champalimaud Foundation Lisbon, Bas Mulder Award granted by the Alpe d'Huzes Foundation and Dutch Cancer Society, and European Research Council Advanced Grant.

Published
2018

48. Traitement des adénomes hypophysaires par radiothérapie stéréotaxique : un protocole alternatif de traitement d’irradiation par CyberKnife® de 35 Gy en cinq fractions

Author

Atallah, V., primary, Kinj, R., additional, Claren, A., additional, Sumodhee, S., additional, Anaïs, G., additional, Gillon, P., additional, Schiappa, R., additional, Sicurani, J., additional, Romain, N., additional, Doyen, J., additional, Hannoun-Lévi, J.-M., additional, and Bondiau, P.-Y., additional

Published
2019
Full Text
View/download PDF

50. Mastectomie de rattrapage ou second traitement conservateur pour second évènement tumoral du sein homolatéral : analyse appariée sur score de propension

Author

Hannoun-Lévi, J.-M., primary, Van Limbergen, E., additional, Gal, J., additional, Schiappa, R., additional, Polgar, C., additional, Kauer-Domer, D., additional, Pasquier, D., additional, Lemanski, C., additional, Racadot, S., additional, Houvenaeghel, G., additional, Guix, B., additional, Bellière-Calandry, A., additional, Loessl, K., additional, Polat, B., additional, Gutierrez, C., additional, Galalae, R., additional, and Strnad, V., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results